Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Galera Therapeutics ( (GRTX) ) has issued an update.
Galera Therapeutics has scheduled its combined 2025 and 2026 Annual Meeting of Stockholders for May 8, 2026, after its 2024 annual meeting was held on February 24, 2025, and is updating key deadlines for shareholder participation as a result of the later date. The company has set April 13, 2026 as the cutoff for shareholders to submit director nominations, other proposals under its bylaws or universal proxy rules, and for proposals to be considered for inclusion in its proxy materials, providing a clear timetable for investors seeking to influence board composition or agenda items at the meeting.
These revised deadlines underscore the company’s adherence to Exchange Act and universal proxy requirements while signaling to shareholders the procedural steps needed to exercise their governance rights. The clarified timeline may affect how active and institutional investors plan engagement, proxy campaigns, or governance initiatives ahead of the 2026 combined meeting.
The most recent analyst rating on (GRTX) stock is a Hold with a $0.05 price target. To see the full list of analyst forecasts on Galera Therapeutics stock, see the GRTX Stock Forecast page.
Spark’s Take on GRTX Stock
According to Spark, TipRanks’ AI Analyst, GRTX is a Neutral.
The score is held back primarily by weak financial performance (no revenue, ongoing operating losses, and limited evidence of sustainable cash generation), despite improved balance-sheet positioning in 2025. Technicals are relatively supportive with an uptrend and positive MACD, while valuation signals are unreliable due to likely non-operating earnings. The corporate event modestly helps by improving capital-structure flexibility but carries dilution risk.
To see Spark’s full report on GRTX stock, click here.
More about Galera Therapeutics
Galera Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing novel therapeutics, though this notice centers on its corporate governance practices rather than its product pipeline or commercial operations.
Average Trading Volume: 58,045
Technical Sentiment Signal: Hold
Current Market Cap: $3.1M
See more data about GRTX stock on TipRanks’ Stock Analysis page.